Drug and Therapeutics Bulletin 1998;36:20-22; doi:10.1136/dtb.1998.36320
Copyright © 1998 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Mefloquine and malaria prophylaxis

Relevant BNF section: 5.4.1

In the UK, mefloquine (Lariam - Roche) has been marketed since 1990 for both malaria prophylaxis and for acute treatment of falciparum malaria. In 1991, we concluded that prophylaxis with mefloquine was appropriate for those travelling to areas where strains of Plasmodium falciparum resistant to chloroquine and proguanil are common.¹ Since then, UK recommendations have changed several times. Recently, mefloquine's use as a prophylactic has been questioned because of reports of neuropsychiatric unwanted effects. This article discusses the place of mefloquine in malaria prophylaxis in light of these concerns.

This article has been cited by other articles:

				A. Croft Extracts from "Clinical Evidence": Malaria: prevention in travellers BMJ, July 15, 2000; 321(7254): 154 - 160. [Abstract] [Full Text]

				R. H Behrens, S. Erny, H. Maradit, S. Houston, J. S Keystone, K. C Kain, A. Croft, and P. Garner Mefloquine to prevent malaria BMJ, June 27, 1998; 316(7149): 1980a - 1980. [Full Text]